Table 1.
The relationship between clinicopathological characteristics, tumour activity, body composition, markers of the systemic inflammatory response and overall survival in patients with lung cancer.
| Characteristics | n = 119 (%) | Univariate Cox regression analysis OS | p-value |
|---|---|---|---|
| Sex | |||
| Male | 57 (47.9) | 1.34 (0.91–1.97) | 0.141 |
| Female | 62 (52.1) | ||
| Age | |||
| < 65 | 17 (14.3) | 1.04 (0.79–1.37) | 0.768 |
| 65–74 | 54 (45.4) | ||
| > 75 | 48 (40.3) | ||
| TNM | |||
| I | 42 (35.3) | 1.40 (1.12–1.74) | 0.003 |
| II | 22 (18.5) | ||
| III | 55 (46.2) | ||
| ECOG-PS | |||
| 0/1 | 68 (57.1) | 0.74 (0.50–1.09) | 0.126 |
| ≥ 2 | 51 (42.9) | ||
| Inflammatory response | |||
| mGPS | |||
| 0 | 58 (48.7) | 1.30 (1.06–1.61) | 0.014 |
| 1 | 20 (16.8) | ||
| 2 | 41 (34.5) | ||
| NLR | |||
| < 3 | 53 (44.5) | 1.38 (1.09–1.76) | 0.009 |
| 3–5 | 35 (29.4) | ||
| > 5 | 31 (26.1) | ||
| MUST | |||
| Low risk | 51 (42.9) | 1.60 (1.21–2.11) | 0.001 |
| Intermediate risk | 52 (43.7) | ||
| High risk | 16 (13.4) | ||
| Body composition | |||
| BMI kg/m2 | |||
| <25 | 56 (47.1) | 0.77 (0.54–1.13) | 0.182 |
| ≥ 25 | 63 (52.9) | ||
| Visceral obesity | |||
| VFA | 134.23 (14.35–577.08) | 1.00 (0.99–1.01) | 0.780 |
| Visceral obesity | |||
| No | 45 (37.8) | 0.81 (0.55–1.20) | 0.292 |
| Yes | 74 (62.2) | ||
| Sarcopenia | |||
| SMI | 44.23 (29.40–74.36) | 1.00 (0.98–1.02) | 0.899 |
| Low SMI | |||
| No | 61 (51.3) | 0.98 (0.67–1.44) | 0.930 |
| Yes | 58 (48.7) | ||
| Myosteatosis | |||
| SMD | 34.53 (9.58–51.24) | 1.03 (1.00–1.05) | 0.043 |
| Low SMD | |||
| No | 45 (37.8) | 0.66 (0.44–0.97) | 0.035 |
| Yes | 74 (62.2) | ||
| PET-CT analysis | |||
| SUVmax | 14.60 (3.10–36.9.) | 1.03 (1.01–1.06) | 0.010 |
| SUVmax > 11.40 | |||
| No | 44 (37.0) | 2.05 (1.34–3.14) | 0.001 |
| Yes | 75 (63.0) | ||
| TLG | 102.66 (3.47–2070.90) | 1.01 (1.00–1.02) | < 0.001 |
| TLG > 68.89 | |||
| No | 47 (29.5) | 2.18 (1.46–3.26) | < 0.001 |
| Yes | 72 (60.5) | ||
TNM Tumour, Node, Metastasis, ECOG-PS Eastern Cooperative Oncology Group Performance Status, mGPS modified Glasgow Prognostic Score, NLR Neutrophil Lymphocyte Ratio, MUST Malnutrition Universal Screening Tool, BMI Body Mass Index, VFA Visceral Fat Area, SMI Skeletal Muscle Index, SMD Skeletal Muscle Density, TLG Total Lesion Glycolysis, SUVmax Standardised Tumour Uptake Value, TLG Total Lesion Glycolysis.